Fast-Seq是一种在学术环境中快速廉价验证包装ssAAV基因组的简单方法。

Q1 Immunology and Microbiology
Lucy H. Maynard, Olivia Smith, Nicolas P. Tilmans, E. Tham, Shayan Hosseinzadeh, Weilun Tan, Ryan T. Leenay, A. May, N. Paulk
{"title":"Fast-Seq是一种在学术环境中快速廉价验证包装ssAAV基因组的简单方法。","authors":"Lucy H. Maynard, Olivia Smith, Nicolas P. Tilmans, E. Tham, Shayan Hosseinzadeh, Weilun Tan, Ryan T. Leenay, A. May, N. Paulk","doi":"10.1089/hum.2019.110","DOIUrl":null,"url":null,"abstract":"Adeno-associated viral (AAV) vectors have shown great promise in gene delivery as evidenced by recent FDA approvals. Despite efforts to optimize manufacturing for GMP productions, few academic labs have the resources to assess vector composition. One critical component of vector quality is packaged genome fidelity. Errors in viral genome replication and packaging can result in the incorporation of faulty genomes with mutations, truncations or rearrangements, compromising vector potency. Thus, sequence validation of packaged genome composition is an important quality control, even in academic settings. We developed Fast-Seq, an end-to-end method for extraction, purification, sequencing and data analysis of packaged ssAAV genomes intended for non-GMP preclinical environments. We validated Fast-Seq on ssAAV vectors with 3 different genome compositions (CAG-tdTomato, EF1⍺-FLuc, CAG-GFP), 3 different genome sizes (2.9kb, 3.6kb, 4.3kb), packaged in 4 different capsid serotypes (AAV1, AAV2, AAV5, AAV8), and produced using the two most common production methods (Baculovirus-Sf9, human HEK293), from both common commercial vendors and academic core facilities supplying academic laboratories. We achieved an average genome coverage of >1,400X and an average ITR coverage of >280X, despite the many differences in composition of each ssAAV sample. When compared to other ssAAV NGS methods for GMP settings, Fast-Seq has several unique advantages: Tn5 transposase-based fragmentation rather than sonication, 125x less input DNA, simpler adapter ligation, compatibility with commonly available inexpensive sequencing instruments, and free open-source data analysis code in a pre-assembled customizable Docker container designed for novices. Fast-Seq can be completed in 18 hours, is more cost-effective than other NGS methods, and is more accurate than Sanger sequencing which is generally only applied at 1-2x sequencing depth. Fast-Seq is a rapid, simple, and inexpensive methodology to validate packaged ssAAV genomes in academic settings.","PeriodicalId":13126,"journal":{"name":"Human Gene Therapy Methods","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/hum.2019.110","citationCount":"2","resultStr":"{\"title\":\"Fast-Seq, a simple method for rapid and inexpensive validation of packaged ssAAV genomes in academic settings.\",\"authors\":\"Lucy H. Maynard, Olivia Smith, Nicolas P. Tilmans, E. Tham, Shayan Hosseinzadeh, Weilun Tan, Ryan T. Leenay, A. May, N. Paulk\",\"doi\":\"10.1089/hum.2019.110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Adeno-associated viral (AAV) vectors have shown great promise in gene delivery as evidenced by recent FDA approvals. Despite efforts to optimize manufacturing for GMP productions, few academic labs have the resources to assess vector composition. One critical component of vector quality is packaged genome fidelity. Errors in viral genome replication and packaging can result in the incorporation of faulty genomes with mutations, truncations or rearrangements, compromising vector potency. Thus, sequence validation of packaged genome composition is an important quality control, even in academic settings. We developed Fast-Seq, an end-to-end method for extraction, purification, sequencing and data analysis of packaged ssAAV genomes intended for non-GMP preclinical environments. We validated Fast-Seq on ssAAV vectors with 3 different genome compositions (CAG-tdTomato, EF1⍺-FLuc, CAG-GFP), 3 different genome sizes (2.9kb, 3.6kb, 4.3kb), packaged in 4 different capsid serotypes (AAV1, AAV2, AAV5, AAV8), and produced using the two most common production methods (Baculovirus-Sf9, human HEK293), from both common commercial vendors and academic core facilities supplying academic laboratories. We achieved an average genome coverage of >1,400X and an average ITR coverage of >280X, despite the many differences in composition of each ssAAV sample. When compared to other ssAAV NGS methods for GMP settings, Fast-Seq has several unique advantages: Tn5 transposase-based fragmentation rather than sonication, 125x less input DNA, simpler adapter ligation, compatibility with commonly available inexpensive sequencing instruments, and free open-source data analysis code in a pre-assembled customizable Docker container designed for novices. Fast-Seq can be completed in 18 hours, is more cost-effective than other NGS methods, and is more accurate than Sanger sequencing which is generally only applied at 1-2x sequencing depth. Fast-Seq is a rapid, simple, and inexpensive methodology to validate packaged ssAAV genomes in academic settings.\",\"PeriodicalId\":13126,\"journal\":{\"name\":\"Human Gene Therapy Methods\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1089/hum.2019.110\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Gene Therapy Methods\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/hum.2019.110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene Therapy Methods","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/hum.2019.110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}
引用次数: 2

摘要

腺相关病毒(AAV)载体在基因传递方面显示出巨大的希望,这是最近FDA批准的证据。尽管努力优化GMP产品的制造,但很少有学术实验室有资源来评估载体组成。载体质量的一个关键组成部分是包装基因组保真度。病毒基因组复制和包装中的错误可能导致有缺陷的基因组与突变、截断或重排的结合,从而损害载体的效力。因此,包装基因组组成的序列验证是一个重要的质量控制,即使在学术设置。我们开发了Fast-Seq,这是一种端到端方法,用于非gmp临床前环境中包装的ssAAV基因组的提取、纯化、测序和数据分析。我们对具有3种不同基因组组成(CAG-tdTomato, EF1 -FLuc, CAG-GFP), 3种不同基因组大小(2.9kb, 3.6kb, 4.3kb), 4种不同衣壳血清型(AAV1, AAV2, AAV5, AAV8)的ssAAV载体进行了Fast-Seq验证,并使用两种最常见的生产方法(Baculovirus-Sf9, human HEK293)生产,这些载体来自常见的商业供应商和提供学术实验室的学术核心设施。尽管每个ssAAV样本的组成存在许多差异,但我们实现了平均基因组覆盖率为1,400X,平均ITR覆盖率为1,280x。与其他用于GMP设置的ssAAV NGS方法相比,Fast-Seq具有几个独特的优势:基于Tn5转位酶的片段化而不是超声,输入DNA减少125倍,适配器连接更简单,与常用的廉价测序仪器兼容,并且在预先组装的可定制的Docker容器中为新手设计了免费的开源数据分析代码。Fast-Seq可在18小时内完成,比其他NGS方法更具成本效益,并且比Sanger测序更准确,Sanger测序通常只应用于1-2x测序深度。Fast-Seq是一种快速、简单、廉价的方法,用于在学术环境中验证包装的ssAAV基因组。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Fast-Seq, a simple method for rapid and inexpensive validation of packaged ssAAV genomes in academic settings.
Adeno-associated viral (AAV) vectors have shown great promise in gene delivery as evidenced by recent FDA approvals. Despite efforts to optimize manufacturing for GMP productions, few academic labs have the resources to assess vector composition. One critical component of vector quality is packaged genome fidelity. Errors in viral genome replication and packaging can result in the incorporation of faulty genomes with mutations, truncations or rearrangements, compromising vector potency. Thus, sequence validation of packaged genome composition is an important quality control, even in academic settings. We developed Fast-Seq, an end-to-end method for extraction, purification, sequencing and data analysis of packaged ssAAV genomes intended for non-GMP preclinical environments. We validated Fast-Seq on ssAAV vectors with 3 different genome compositions (CAG-tdTomato, EF1⍺-FLuc, CAG-GFP), 3 different genome sizes (2.9kb, 3.6kb, 4.3kb), packaged in 4 different capsid serotypes (AAV1, AAV2, AAV5, AAV8), and produced using the two most common production methods (Baculovirus-Sf9, human HEK293), from both common commercial vendors and academic core facilities supplying academic laboratories. We achieved an average genome coverage of >1,400X and an average ITR coverage of >280X, despite the many differences in composition of each ssAAV sample. When compared to other ssAAV NGS methods for GMP settings, Fast-Seq has several unique advantages: Tn5 transposase-based fragmentation rather than sonication, 125x less input DNA, simpler adapter ligation, compatibility with commonly available inexpensive sequencing instruments, and free open-source data analysis code in a pre-assembled customizable Docker container designed for novices. Fast-Seq can be completed in 18 hours, is more cost-effective than other NGS methods, and is more accurate than Sanger sequencing which is generally only applied at 1-2x sequencing depth. Fast-Seq is a rapid, simple, and inexpensive methodology to validate packaged ssAAV genomes in academic settings.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human Gene Therapy Methods
Human Gene Therapy Methods BIOTECHNOLOGY & APPLIED MICROBIOLOGY-GENETICS & HEREDITY
CiteScore
5.80
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信